(Q41418810)

English

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

scientific article published on 3 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

0 references

multicenter clinical trial

0 references

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

David A. Isenberg

1

object named as

D A Isenberg

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Michelle A. Petri

2

object named as

M Petri

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Kenneth C. Kalunian

3

object named as

K Kalunian

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

author name string

Y Tanaka

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

M B Urowitz

5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

R W Hoffman

6

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

M Morgan-Cox

7

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

N Iikuni

8

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

M Silk

9

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

D J Wallace

10

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

language of work or name

0 references

publication date

3 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

75

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

323-331

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Regulated expression of BAFF-binding receptors during human B cell differentiation.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Novel evidence-based systemic lupus erythematosus responder index

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-207653

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2015-207653

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41418810&oldid=2096908694"